]> 2026-04-12T03:50:15-07:00 Gleevec (Imatinib) 0 en Gleevec (Imatinib) is at a moderate toxicity level. This is because while it does have side effects such as fluid retention, nausea, muscle cramps, rashes, and fatigue, these are common to most treatments and they vary from patient to patient. Also, it has not been specifically approved for glioma treatment, indicating that it might have unexpected results, slightly increasing the risk factor. However, it has shown some potential benefits in early research, hence the moderate, not high, toxicity rating. 2025-01-18T08:22:57Z 2460693.8492708 Gleevec (Imatinib) 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","Gleevec (also known as imatinib), a small molecule which targets a specific gene involved\nin the growth of a form of leukemia, received a great deal of publicity because of its\nunprecedented effectiveness. As will be discussed later, this general strategy of\nidentifying the growth signals for tumor growth and then targeting those signals, or their\nreceptors, is one of the major new areas in cancer research. Such growth signaling\nchannels often are involved in several different types of cancer. Although Gleevec was\ndeveloped specifically for chronic myelogenous leukemia, it also has been shown to\ninhibit a more general type of growth signal, platelet-derived growth factor (PDGF),\nwhich is also involved in the growth of gliomas and other forms of cancer (e.g., small-\ncell lung cancer). Laboratory research has supported the importance of this similarity in\nthat gleevec has been shown to strongly inhibit glioma growth, with the result that there\nnow have been a number of studies reporting its use with high-grade gliomas.\n\nThe generally disappointing results using gleevec for brain tumors may have occurred\n\nfor several different reasons. It may not readily cross the blood-brain-barrier, and it may\nengender different mechanisms of resistance than other treatment agents. In the study of\ngleevec for leukemia, for example, high levels of autophagy have been observed, which\ncan be inhibited by the concurrent use of chloroquine or other autophagy inhibitors.\n\nAn important variation in the use of gleevec was to restrict its usage to patients with\nrecurrent tumors who tested positive for overexpression of the platelet-derived growth\nfactor receptor (90). PDGFR is overexpressed in 50-65% of tumors, especially tumors\n\n\nlabeled secondary glioblastomas, which are believed to have evolved from lower-grade\ntumors (in contrast to de novo glioblastomas that occur without such evolution). For this\nrestricted patient population, the PFS-6 value was 53%."] Gleevec (Imatinib)# ERRa3f62c6665776505f0db7c26c19aebf1 Has treatment name 102 en Has treatment name